(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Slides:



Advertisements
Similar presentations
Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.
Advertisements

HEART-LUNG TRANSPLANTATION
HEART TRANSPLANTATION
Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.
Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.
José L. Morales et al. JACEP 2017;j.jacep
HEART TRANSPLANTATION
Baseline characteristics of patients
Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)
Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.
Volume 68, Issue 2, Pages (August 2005)
Volume 6, Issue 12, Pages (December 2009)
Belinda Gray et al. JCHF 2013;1:
David F. Katz et al. JACEP 2016;j.jacep
Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.
HEART-LUNG TRANSPLANTATION
HEART-LUNG TRANSPLANTATION
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Mintu P. Turakhia et al. JACEP 2016;2:
Kaplan-Meier curves for overall survival (OS) probability.
Svend A. Mortensen et al. JCHF 2014;2:
Prabhat Kumar et al. JACEP 2016;j.jacep
David F. Katz et al. JACEP 2017;3:20-28
Neal A. Chatterjee et al. JCHF 2014;2:
Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.
HEART-LUNG TRANSPLANTATION
Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.
Volume 8, Issue 3, Pages (March 2011)
Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.
Kaplan-Meier analysis for the MACE-free or VA-free survival in patients with definite CS (A and C) or suspected CS (B and D) stratified by localisation.
Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.
Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.
Figure 1 Patient selection
Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.
(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.
Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.
Perioperative associates of exaggerated heart rate responses pre-exercise. Perioperative associates of exaggerated heart rate responses pre-exercise. (A)
Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (
Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.
Ejection fraction preoperatively and at follow-up in conventional (C) and no-touch (NT) groups. Ejection fraction preoperatively and at follow-up in conventional.
Favorable Results of Implantable Cardioverter-Defibrillator Implantation in Patients Older Than 70 Years  Kara J Quan, Jai H Lee, Otto Costantini, Anastasios.
Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)
Kaplan-Meier survival estimates for major cardiovascular events.
Results of comparisons of treatments in the network.
Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.
Comparison of survival in patients with BAV (A) and TAV (B) in the US cohort using Kaplan-Meier curves, stratified by whether or not they had suffered.
Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.
Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test
Survival curves according to the presence of late gadolinium enhancement (LGE) and elevated high-sensitivity C reactive protein (hs-CRP). Survival curves.
Time to first event analysis revealed a significant difference in estimated event-free (death or hospitalisation) survival between patients with left ventricular.
Kaplan-Meier survival curves for canine patients with (n = 3; huTyr Ab+) and without (n = 6; huTyr Ab-) positive humoral responses to the xenogeneic huTyr.
Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (
Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.
Kaplan-Meier estimates of all-cause mortality at 30 days.
Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.
Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.
Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.
Survival of subjects listed for heart transplantation with different spirometric ventilatory patterns. Survival of subjects listed for heart transplantation.
Survival of subjects listed for heart transplantation with and without spirometry. Survival of subjects listed for heart transplantation with and without.
Heritability estimates in percentages using structural equations modelling for primary trait phenotypes in DCM (LVEF and LVEDD), HCM (IVSd) and LQTS (QTc).
Volume 16, Issue 6, Pages (June 2019)
Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.
(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm
Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.
HEART-LUNG TRANSPLANTATION
Survival free of atrial fibrillation after implantation of an implantable cardioverter defibrillator in our series (151 patients): overall population (solid.
Presentation transcript:

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation or appropriate ICD therapy included as events. Median age estimate for LMNA mutation carriers to first event was 63 years (CI 53 to 72) compared with 68 years (CI 64 to 72) for DCM controls. No statistically significant difference in event-free survival between the two groups was observed (p=0.463, log-rank test). (B). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Deaths, heart transplants, resuscitations, appropriate ICD therapy or pacemaker implantations included as events. Median age estimate for LMNA mutation carriers was 48 years (CI 42 to 53) compared with 60 years (CI 55 to 64) for DCM controls (p=0.005, log-rank test). DCM, dilated cardiomyopathy; ICD, implantable cardioverter-defibrillator. Laura Ollila et al. Open Heart 2017;4:e000474 ©2017 by British Cardiovascular Society